DCT

1:26-cv-00977

Eli Lilly Co v. DR Reddys Laboratories Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00977, D. Del., 08/06/2026
  • Venue Allegations: The complaint alleges that venue is proper in this District under 28 U.S.C. §§ 1391 and 1400(b) and/or Federal Rule of Civil Procedure 4(k)(2); the allegations regarding Defendants' transaction of business in Delaware and purposeful availment of the state's laws are pleaded as the basis for personal jurisdiction rather than venue.
  • Core Dispute: Plaintiff alleges that Defendants' submission of Abbreviated New Drug Applications (ANDAs) to the FDA for approval to market generic versions of Mounjaro® and Zepbound® infringes ten U.S. patents covering the active ingredient tirzepatide, its pharmaceutical compositions, and its methods of use.
  • Technical Context: The technology relates to tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used for glycemic control in type 2 diabetes and for chronic weight management.
  • Key Procedural History: This is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2) following Plaintiff's receipt of Paragraph IV certification notice letters from Defendants, which assert that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by the proposed generic products.

Case Timeline

Date Event
2015-01-09 ’780 Patent Priority Date
2016-10-25 '780 Patent Issue Date
2018-06-22 ’820, ’623, ’755, ’756, and ’404 Patents Priority Date
2018-07-23 ’987, ’382, ’758, and ’740 Patents Priority Date
2022-05-13 FDA grants approval for Mounjaro®
2022-06-14 '820 Patent Issue Date
2023-11-08 FDA grants approval for Zepbound®
2024-03-05 '623 Patent Issue Date
2025-05-13 '987 Patent Issue Date
2025-07-01 '382 Patent Issue Date
2025-10-28 '755, '756, and '758 Patents Issue Date
2026-05-05 '740 Patent Issue Date
2026-05-19 '404 Patent Issue Date
2026-07-14 Defendants' Notice Letters dated
2026-07-15 Plaintiff receives Defendants' Notice Letters
2026-08-06 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,474,780 - "GIP and GLP-1 Co-agonist Compounds"

  • Patent Identification: U.S. Patent No. 9,474,780, "GIP and GLP-1 Co-agonist Compounds", issued October 25, 2016 Compl. ¶24

The Invention Explained

  • Problem Addressed: The complaint explains that tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist for treating conditions like type 2 diabetes and obesity Compl. ¶20 The development of such dual-agonist peptides seeks to provide more effective therapies than existing treatments.
  • The Patented Solution: The '780 Patent claims the specific chemical structure of the tirzepatide compound Compl. ¶54 This molecule is designed to act as a co-agonist on both GIP and GLP-1 receptors, providing a dual mechanism of action for improving glycemic control and managing weight Compl. ¶20
  • Technical Importance: Tirzepatide is a single molecule that acts as an agonist of both the GIP and GLP-1 receptors, combining two distinct incretin hormone pathways in one dual-agonist compound Compl. ¶20

Key Claims at a Glance

  • The complaint asserts at least Claim 1 Compl. ¶55
  • Independent Claim 1 covers:
    • A compound of Formula: YX1EGTFTSDYSIX2LDKIAQKAX3VQWLIAGGPSSGAPPPS; wherein X1 is Aib; X2 is Aib;
    • K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(yGlu)a-CO—(CH2)b—CO2H wherein a is 1 to 2 and b is 10 to 20;
    • X3 is Phe or 1-Nal;
    • and the C-terminal amino acid is optionally amidated as a C-terminal primary amide (SEQ ID NO: 11), or a pharmaceutically acceptable salt thereof Compl. ¶54

U.S. Patent No. 11,357,820 - "GIP/GLP1 Agonist Compositions"

  • Patent Identification: U.S. Patent No. 11,357,820, "GIP/GLP1 Agonist Compositions", issued June 14, 2022 Compl. ¶26

The Invention Explained

  • Problem Addressed: The patent background describes a "desire for compositions of tirzepatide providing acceptable stability and acceptable patient injection site experience" ’820 Patent, col. 1:16-19 It further notes that some formulation components can cause painful stinging at the injection site and that it is desirable for compositions to be isotonic with body fluids ’820 Patent, col. 4:1-15
  • The Patented Solution: The patent discloses a pharmaceutical composition comprising tirzepatide, NaCl as a tonicity agent, and dibasic sodium phosphate as a buffer ’820 Patent, abstract ’820 Patent, col. 1:4-7 This specific combination of excipients is intended to provide a stable, injectable formulation of tirzepatide that is well-tolerated by patients upon subcutaneous administration ’820 Patent, col. 1:4-10
  • Technical Importance: For biologic drugs administered via injection, creating a commercially viable formulation that remains stable over its shelf-life and minimizes patient discomfort is critical for ensuring patient compliance and therapeutic success.

Key Claims at a Glance

  • The complaint asserts at least Claim 1 Compl. ¶72
  • Independent Claim 1 covers:
    • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
    • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; and
    • dibasic sodium phosphate Compl. ¶71

U.S. Patent No. 11,918,623 - "GIP/GLP1 Agonist Compositions"

  • Patent Identification: U.S. Patent No. 11,918,623, "GIP/GLP1 Agonist Compositions", issued March 5, 2024 Compl. ¶28
  • Technology Synopsis: This patent covers a method of treating obesity. The method involves administering a pharmaceutical composition containing tirzepatide within specific concentration ranges for the active ingredient and various excipients, including dibasic sodium phosphate, NaCl, and optionally phenol Compl. ¶88
  • Asserted Claims: At least Claim 1 is asserted Compl. ¶89
  • Accused Features: Defendants' Proposed ANDA No. 220664 Product is accused of infringing because its proposed labeling allegedly instructs and encourages the treatment of obesity using a composition that meets the claim limitations Compl. ¶¶89-90

U.S. Patent No. 12,295,987 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

  • Patent Identification: U.S. Patent No. 12,295,987, "Methods of Using a GIP/GLP1 Co-agonist for Diabetes", issued May 13, 2025 Compl. ¶30
  • Technology Synopsis: This patent claims a method of treating type 2 diabetes using a specific four-step dose-titration regimen. The method specifies a GIP:GLP-1 peptide with a particular agonist potency ratio and defines the relative dosages for each of the four steps (e.g., the first dose is about 25% of the fourth dose) Compl. ¶106
  • Asserted Claims: At least Claim 1 is asserted Compl. ¶107
  • Accused Features: Defendants' Proposed ANDA No. 220663 Product is accused of infringing because its proposed labeling allegedly instructs and encourages treating type 2 diabetes with the claimed multi-step dosing regimen Compl. ¶107

U.S. Patent No. 12,343,382 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

  • Patent Identification: U.S. Patent No. 12,343,382, "Methods of Using a GIP/GLP1 Co-agonist for Therapy", issued July 1, 2025 Compl. ¶32
  • Technology Synopsis: This patent claims methods for treating type 2 diabetes and improving weight management. The methods comprise administering an "escalation dose" (from a specific group of dosages) for at least two weeks, followed by administering a "maintenance dose" (from another specific group of dosages) for at least two weeks Compl. ¶124 Compl. ¶126
  • Asserted Claims: At least Claims 1 and 11 are asserted Compl. ¶128
  • Accused Features: Defendants' Proposed ANDA Products are accused of infringing because their proposed labeling allegedly instructs and encourages using the claimed escalation and maintenance dosing regimens for treating type 2 diabetes and improving weight management Compl. ¶125 Compl. ¶127

U.S. Patent No. 12,453,755 - "GIP/GLP1 Agonist Compositions"

  • Patent Identification: U.S. Patent No. 12,453,755, "GIP/GLP1 Agonist Compositions", issued October 28, 2025 Compl. ¶34
  • Technology Synopsis: This patent covers a method of treating diabetes by administering an effective dose of a pharmaceutical composition. The composition is defined by specific concentration ranges for tirzepatide, dibasic sodium phosphate, NaCl, and optionally phenol Compl. ¶146
  • Asserted Claims: At least Claim 1 is asserted Compl. ¶147
  • Accused Features: Defendants' Proposed ANDA No. 220663 Product is accused of infringing because its proposed labeling allegedly instructs and encourages treating diabetes with a composition that meets the claimed concentration ranges Compl. ¶147

U.S. Patent No. 12,453,756 - "GIP/GLP1 Agonist Compositions"

  • Patent Identification: U.S. Patent No. 12,453,756, "GIP/GLP1 Agonist Compositions", issued October 28, 2025 Compl. ¶36
  • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide and a specific concentration range of NaCl. A key limitation is that the final composition must have a pH within the range of about 6.5 to 7.5 Compl. ¶164
  • Asserted Claims: At least Claim 1 is asserted Compl. ¶165
  • Accused Features: Defendants' Proposed ANDA Products are accused of being pharmaceutical compositions that meet the claimed limitations regarding tirzepatide, NaCl concentration, and pH range Compl. ¶165

U.S. Patent No. 12,453,758 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

  • Patent Identification: U.S. Patent No. 12,453,758, "Methods of Using a GIP/GLP1 Co-agonist for Diabetes", issued October 28, 2025 Compl. ¶38 The patent's own front page bears this same title, which the complaint reproduces accurately, although the asserted claims relate to weight management Compl. ¶38
  • Technology Synopsis: This patent claims a method of improving weight management using a specific four-step dose-titration regimen. The method specifies a GIP:GLP-1 peptide with a particular agonist potency ratio and defines the relative dosages for each of the four steps (e.g., the first dose is about 25% of the fourth dose) Compl. ¶181
  • Asserted Claims: At least Claim 1 is asserted Compl. ¶182
  • Accused Features: Defendants' Proposed ANDA No. 220664 Product is accused of infringing because its proposed labeling allegedly instructs and encourages improving weight management with the claimed multi-step dosing regimen Compl. ¶182

U.S. Patent No. 12,616,740 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

  • Patent Identification: U.S. Patent No. 12,616,740, "Methods of Using a GIP/GLP1 Co-agonist for Therapy", issued May 5, 2026 Compl. ¶40
  • Technology Synopsis: This patent claims methods for treating type 2 diabetes and obesity by administering tirzepatide in once-weekly doses. The methods involve a specific dose-escalation schedule, starting with 2.5 mg for four weeks and increasing by 2.5 mg increments for at least four weeks at each new dose level, up to a maintenance dose Compl. ¶199 Compl. ¶201
  • Asserted Claims: At least Claims 1 and 6 are asserted Compl. ¶203
  • Accused Features: Defendants' Proposed ANDA Products are accused of infringing because their proposed labeling allegedly instructs and encourages the use of the claimed once-weekly dose escalation schedule for treating diabetes and obesity Compl. ¶200 Compl. ¶202

U.S. Patent No. 12,629,404 - "GIP/GLP1 Agonist Compositions"

  • Patent Identification: U.S. Patent No. 12,629,404, "GIP/GLP1 Agonist Compositions", issued May 19, 2026 Compl. ¶42
  • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide, a specific range of NaCl, and a specific pH range. A key negative limitation is that "the composition is free of preservative" Compl. ¶221
  • Asserted Claims: At least Claim 1 is asserted Compl. ¶222
  • Accused Features: Defendants' Proposed ANDA Products are accused of being pharmaceutical compositions that meet the claimed limitations, including being free of preservative Compl. ¶222

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are Defendants' "Proposed ANDA Products" submitted to the FDA under ANDA Nos. 220663 and 220664 Compl. ¶1

Functionality and Market Context

  • The Proposed ANDA Products are generic versions of Plaintiff's Mounjaro® and Zepbound® products, containing the active pharmaceutical ingredient tirzepatide (Compl. ¶1; Compl. ¶48). They are formulated as autoinjectors and vials in various strengths (e.g., 2.5 mg/0.5 mL to 15 mg/0.5 mL) for subcutaneous administration Compl. ¶1
  • Defendants' ANDAs rely on the safety and efficacy data of Lilly's approved drugs and seek approval to market their products for the same indications, which include improving glycemic control in type 2 diabetes and for chronic weight management (Compl. ¶¶1; Compl. ¶49). The complaint provides a structural formula for tirzepatide, which is the active ingredient in the accused products Compl. p. 10

IV. Analysis of Infringement Allegations

'780 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of Formula: YX1EGTFTSDYSIX2LDKIAQKAX3VQWLIAGGPSSGAPPPS...or a pharmaceutically acceptable salt thereof. Defendants' Proposed ANDA Products contain tirzepatide, which is a compound with the structural formula corresponding to the claim. ¶55 col. 9:55-65

'820 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; The Proposed ANDA Products are pharmaceutical compositions that comprise tirzepatide or a salt thereof. ¶72 col. 1:4-7
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; The Proposed ANDA Products are pharmaceutical compositions that comprise NaCl at a concentration within the claimed range. ¶72 col. 1:33-35
and dibasic sodium phosphate. The Proposed ANDA Products are pharmaceutical compositions that comprise dibasic sodium phosphate. ¶72 col. 1:40-45

Identified Points of Contention

  • Scope Questions: For the '780 Patent, the complaint alleges that Defendants' notice letters do not contest that the patent covers the Proposed ANDA Products Compl. ¶58 The complaint separately recites that Defendants' Paragraph IV certifications assert the '780 Patent is invalid, unenforceable, and/or not infringed Compl. ¶57, so which of these defenses will predominate for this patent remains an open question.
  • Technical Questions: For the '820 Patent and other formulation patents, a central question will be evidentiary: does the specific formulation of Defendants' Proposed ANDA Products, once disclosed, actually meet the claimed concentration ranges for each excipient (e.g., NaCl, dibasic sodium phosphate) and physical properties (e.g., pH)? The complaint alleges that the Proposed ANDA Products are covered by the asserted claims Compl. ¶72 Compl. ¶165, but the precise formulation has not yet been disclosed, making this a fact-intensive inquiry dependent on discovery.
  • Induced Infringement: For the method-of-use patents ('623, '987, '382, '755, '758, '740), a key question will be whether Defendants' proposed product labeling will be found to instruct or encourage physicians and patients to administer the generic drug in a manner that practices the specific steps of the asserted method claims, such as the detailed dose-titration schedules Compl. ¶89 Compl. ¶107 Compl. ¶125

V. Key Claim Terms for Construction

'780 Patent

  • The complaint does not provide sufficient detail for analysis of key claim terms for the '780 patent, as the infringement allegation is a direct structural identity match. The complaint's allegations raise the question whether the dispute will center on validity rather than claim construction.

'820 Patent

  • The Term: "dibasic sodium phosphate"
  • Context and Importance: This term is critical because different forms of sodium phosphate (e.g., anhydrous, heptahydrate) have different molecular weights, which could impact whether a given formulation's concentration falls within the claimed ranges. The complaint notes that Lilly's own products contain "sodium phosphate dibasic heptahydrate" Compl. ¶21, while the claim is not so specific. Practitioners may focus on this term because its construction could determine the scope of infringing formulations.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent claims recite the general term "dibasic sodium phosphate" without specifying a hydration state '820 Patent, claim 1 The specification also refers to the ingredient generally, which may support an interpretation that covers any pharmaceutically acceptable form of the salt ('820 Patent, col. 1:7).
    • Evidence for a Narrower Interpretation: The detailed examples in the specification consistently use "Sodium phosphate dibasic 7H2O" '820 Patent, Table 5 '820 Patent, Table 7 A defendant may argue that these consistent examples limit the scope of the broader claim term to the heptahydrate form explicitly disclosed in the embodiments.

VI. Other Allegations

Indirect Infringement

  • The complaint alleges both active inducement (35 U.S.C. § 271(b)) and contributory infringement (35 U.S.C. § 271(c)) for the asserted patents generally, including the '780 compound patent and the '820 and '404 composition patents Compl. ¶64 Compl. ¶65 Compl. ¶81 Compl. ¶82 Compl. ¶231 Compl. ¶232 It pleads that Defendants' proposed product labeling will instruct and encourage healthcare providers and patients to administer the generic products according to the patented methods for treating diabetes and obesity, including specific dose escalation and maintenance regimens Compl. ¶¶97-99 Compl. ¶¶115-117 Compl. ¶¶135-138

Willful Infringement

  • The complaint does not contain a formal count for willful infringement, but it lays the factual groundwork for such a claim. It alleges that Defendants had pre-suit knowledge of the asserted patents because the patents are listed in the FDA's Orange Book for Mounjaro® and Zepbound®, and because Defendants specifically identified the patents in their Paragraph IV Notice Letters to Lilly Compl. ¶63 Compl. ¶80 Compl. ¶96 Compl. ¶114

VII. Analyst’s Conclusion: Key Questions for the Case

  • A central issue for the case will be one of patent validity. This is a Hatch-Waxman action in which Defendants' Paragraph IV certifications assert that the asserted patents are invalid, unenforceable, and/or will not be infringed; the complaint does not identify the specific invalidity theories Defendants intend to pursue. The complaint's allegation that Defendants do not contest that the '780 compound patent "cover[s]" their product raises the question of which defenses will frame the dispute for that patent Compl. ¶58
  • A key evidentiary question will be one of compositional identity. For the formulation patents (e.g., '820, '756, '404), the dispute may turn on whether the precise, undisclosed formulation of the Defendants' Proposed ANDA Products literally meets the claimed concentration ranges, pH values, and excipient lists. This will be a fact-intensive inquiry dependent on discovery and expert testimony.
  • A third core issue will be one of induced infringement for the method-of-use patents (e.g., '987, '382, '740). The analysis will focus on whether the language in the Defendants' proposed product label will be found to specifically instruct or encourage clinicians and patients to perform the exact multi-step dosing and titration regimens required by the asserted method claims.